Breaking Finance News

Zacks Investment Research downgraded GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) to Sell in a report released today.

Zacks Investment Research has downgraded GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) to Sell in a report released on Thursday July 06, 2017.

Yesterday GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) traded 0.41% higher at $108.00. The company’s 50-day moving average is $107.57 and its 200-day moving average is $113.04. The last closing price is down -9.00% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time. 179,047 shares of the stock were exchanged, down from an average trading volume of 297,005

Recent Performance Chart

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH)

GW Pharmaceuticals PLC- ADR has 52 week low of $79.62 and a 52 week high of $137.88 and has a market capitalization of $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 8 brokers have issued a research note on the company. The average stock price target is $139.75 with 2 brokers rating the stock a strong buy, 5 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH)

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.